General Announcement::Glenmark Pharmaceuticals receives ANDA approval for Esomeprazole Magnesium Delayed-Release Capsules

Issuer & Securities

Issuer/ Manager
GLENMARK PHARMACEUTICALS LIMITED
Securities
GLENMARK PH US$200M4.5%210802 - XS1456577334 - 4N4B
GLENMARK PHARM US$170M2%220628 - XS1426780125 - 4G8B
Stapled Security
No

Announcement Details

Announcement Title
General Announcement
Date &Time of Broadcast
14-May-2019 12:58:46
Status
New
Announcement Sub Title
Glenmark Pharmaceuticals receives ANDA approval for Esomeprazole Magnesium Delayed-Release Capsules
Announcement Reference
SG190514OTHR6EUZ
Submitted By (Co./ Ind. Name)
Glenmark Pharmaceuticals Limited
Designation
Company Secretary & Compliance Officer
Effective Date and Time of the event
14/05/2019 10:28:00
Description (Please provide a detailed description of the event in the box below)
Glenmark Pharmaceuticals receives ANDA approval for Esomeprazole Magnesium Delayed-Release Capsules USP, 20 mg and 40 mg

Attachments

PR_SGX_14.05.2019.pdf
Total size =299K